.
your current city: mumbai
.
'indian ip and liabilities law barrier to pharma r&d investment'
.
phil lempert: it's affordability. it's convenience. it's not having a lot of waste. people are more concerned about waste than ever before.
.
.
following close on aimovig's heels are three other drugs that target cgrp: fremanezumab, galcanezumab, and eptinezumab (which is given by iv).
https://grassfed.us/Remmen-grandma-of-Gonazlez-from-Incheon
share on facebook facebook
.